Insider Selling: Shockwave Medical Inc (NASDAQ:SWAV) Director Sells $35,945.00 in Stock

Shockwave Medical Inc (NASDAQ:SWAV) Director Antoine Papiernik sold 455 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $79.00, for a total transaction of $35,945.00. Following the completion of the sale, the director now owns 2,701 shares of the company’s stock, valued at $213,379. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Antoine Papiernik also recently made the following trade(s):

  • On Friday, October 9th, Antoine Papiernik sold 1,126 shares of Shockwave Medical stock. The shares were sold at an average price of $79.00, for a total value of $88,954.00.
  • On Monday, October 5th, Antoine Papiernik sold 24,587 shares of Shockwave Medical stock. The shares were sold at an average price of $77.15, for a total value of $1,896,887.05.
  • On Thursday, October 1st, Antoine Papiernik sold 17,744 shares of Shockwave Medical stock. The stock was sold at an average price of $75.32, for a total value of $1,336,478.08.
  • On Monday, September 28th, Antoine Papiernik sold 17,347 shares of Shockwave Medical stock. The shares were sold at an average price of $73.13, for a total value of $1,268,586.11.
  • On Friday, September 18th, Antoine Papiernik sold 12,653 shares of Shockwave Medical stock. The stock was sold at an average price of $73.19, for a total value of $926,073.07.
  • On Monday, September 14th, Antoine Papiernik sold 78,528 shares of Shockwave Medical stock. The shares were sold at an average price of $67.98, for a total transaction of $5,338,333.44.
  • On Thursday, August 27th, Antoine Papiernik sold 160,440 shares of Shockwave Medical stock. The stock was sold at an average price of $60.43, for a total transaction of $9,695,389.20.
  • On Tuesday, August 25th, Antoine Papiernik sold 60,657 shares of Shockwave Medical stock. The stock was sold at an average price of $60.05, for a total transaction of $3,642,452.85.
  • On Thursday, August 20th, Antoine Papiernik sold 33,822 shares of Shockwave Medical stock. The shares were sold at an average price of $60.01, for a total transaction of $2,029,658.22.
  • On Wednesday, August 12th, Antoine Papiernik sold 1,300 shares of Shockwave Medical stock. The stock was sold at an average price of $55.02, for a total transaction of $71,526.00.

Shares of NASDAQ SWAV opened at $78.22 on Friday. The company has a quick ratio of 13.58, a current ratio of 14.90 and a debt-to-equity ratio of 0.10. The company has a market cap of $2.66 billion, a P/E ratio of -37.25 and a beta of 0.98. Shockwave Medical Inc has a 52 week low of $22.01 and a 52 week high of $79.25. The business has a 50-day simple moving average of $69.97 and a two-hundred day simple moving average of $50.74.

Shockwave Medical (NASDAQ:SWAV) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.06. The firm had revenue of $10.30 million for the quarter, compared to the consensus estimate of $8.35 million. Shockwave Medical had a negative net margin of 126.34% and a negative return on equity of 35.68%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.38) earnings per share. Equities research analysts anticipate that Shockwave Medical Inc will post -2.2 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Shockwave Medical by 6.3% in the second quarter. FMR LLC now owns 5,067,390 shares of the company’s stock worth $240,042,000 after purchasing an additional 302,550 shares during the period. Wellington Management Group LLP increased its position in shares of Shockwave Medical by 57.0% in the first quarter. Wellington Management Group LLP now owns 2,005,121 shares of the company’s stock worth $66,530,000 after purchasing an additional 727,621 shares during the last quarter. Vanguard Group Inc. lifted its position in Shockwave Medical by 15.4% during the second quarter. Vanguard Group Inc. now owns 2,002,968 shares of the company’s stock valued at $94,880,000 after purchasing an additional 267,559 shares during the last quarter. Gilder Gagnon Howe & Co. LLC grew its stake in Shockwave Medical by 34.3% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,914,242 shares of the company’s stock worth $90,678,000 after buying an additional 489,096 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Shockwave Medical by 287.0% in the 1st quarter. Wells Fargo & Company MN now owns 1,143,343 shares of the company’s stock worth $37,936,000 after buying an additional 847,901 shares during the last quarter. Hedge funds and other institutional investors own 83.75% of the company’s stock.

Several equities analysts recently commented on SWAV shares. BidaskClub upgraded Shockwave Medical from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 19th. Canaccord Genuity increased their price target on Shockwave Medical from $60.00 to $87.00 and gave the stock a “buy” rating in a research note on Friday. Zacks Investment Research raised Shockwave Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 15th. Wells Fargo & Company upped their price objective on shares of Shockwave Medical from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday. Finally, Morgan Stanley lifted their target price on shares of Shockwave Medical from $42.00 to $55.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 12th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $58.13.

Shockwave Medical Company Profile

ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Further Reading: Stochastic Momentum Index (SMI)

Insider Buying and Selling by Quarter for Shockwave Medical (NASDAQ:SWAV)

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.